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Abstract Botulinum neurotoxin E (BoNT E) cleaves SNAP-25
at the C-terminal domain releasing a 26-mer peptide. This
peptide product may act as an excitation-secretion uncoupling
peptide (ESUP) to inhibit vesicle fusion and thus contribute to
the efficacy of BoNT E in disabling neurosecretion. We have
addressed this question using a synthetic 26-mer peptide which
mimics the amino acid sequence of the naturally released peptide,
and is hereafter denoted as ESUP E. This synthetic peptide is a
potent inhibitor of Ca2+-evoked exocytosis in permeabilized
chromaffin cells and reduces neurotransmitter release from
identified cholinergic synapses in in vitro buccal ganglia of
Aplysia californica. In chromaffin cells, both ESUP E and BoNT
E abrogate the slow component of secretion without affecting the
fast, Ca2+-mediated fusion event. Analysis of immunoprecipi-
tates of the synaptic ternary complex involving SNAP-25,
VAMP and syntaxin demonstrates that ESUP E interferes with
the assembly of the docking complex. Thus, the efficacy of
BoNTs as inhibitors of neurosecretion may arise from the
synergistic action of cleaving the substrate and releasing peptide
products that disable the fusion process by blocking specific steps
of the exocytotic cascade.
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1. Introduction
A widely held view considers that the process of vesicle
fusion with the plasma membrane which occurs during neuro-
nal exocytosis is mediated by SNARE proteins [1^5]. This
family of membrane proteins provides a speci¢c means of
pairing vesicles (v-SNAREs) with target (t-SNAREs) mem-
branes [1^5]. Clostridial neurotoxins are metalloproteases that
cleave speci¢c components of the v-SNARE and t-SNARE
and abolish neurotransmitter release. Botulinum neurotoxins
(BoNT) B, D, F, and G, and the structurally related tetanus
toxin speci¢cally cleave VAMP at di¡erent sites [6,7] ; BoNT
A and E cleave SNAP-25 at the C-terminus [8,9], and BoNT
C cuts syntaxin and SNAP-25 [10,11]. Proteolysis of each of
these substrates produces a truncated protein and releases a
peptide product [6^11]. It has been proposed that these pep-
tide products may also prevent the formation of the core
complex and thereby abrogate Ca2-triggered exocytosis
[12,13]. This hypothesis is supported by the ¢nding that trun-
cated fusion proteins and synthetic peptides that mimic the
amino acid sequence of segments from synaptotagmin [14,15],
SNAPs [16], synaptobrevin [17], syntaxin [18], Ca2 channels
[19], and SNAP-25 [12,13,20] are speci¢c inhibitors of neuro-
secretion. In particular, a 20-mer peptide encompassing the C-
terminal domain of SNAP-25 blocked exocytosis by inhibiting
vesicle docking in permeabilized chroma⁄n cells [12,13]. The
term ESUP (excitation-secretion uncoupling peptide) was
coined to highlight this inhibitory activity [12]. Although these
results suggest that peptide products resulting from substrate
cleavage by BoNTs may block vesicle fusion, experimental
support to substantiate this notion is still limited.
Here, we show that a 26-mer peptide corresponding to the
amino acid sequence of the peptide product released by BoNT
E cleavage of SNAP-25, referred to as ESUP E, e⁄ciently and
selectively blocks Ca2-evoked exocytosis in chroma⁄n cells
and neurotransmitter release in Aplysia cholinergic synapses.
Our results are consistent with the notion that ESUP E pre-
vents vesicle docking by interfering with the assembly of the
synaptic ternary complex formed by SNAP-25, VAMP and
syntaxin.
2. Material and methods
2.1. Reagents
[3H]Noradrenaline was from DuPont-NEN (Boston, MA). t-Boc
and Fmoc amino acids, with standard side chain protecting groups,
were obtained from Applied Biosystems (Foster City, CA), NovaBio-
chem (La Jolla, CA) or Peninsula Laboratories (Belmont, CA). Sol-
vents, reagents and resins for peptide synthesis were obtained from
Applied Biosystems (Foster City, CA), Percoll from Pharmacia, col-
lagenase (EC 3.4.24.3) from Boehringer Mannheim (Germany), anti-
SNAP-25 mAb (clone SM81) from Sternberger (Baltimore, MD),
anti-syntaxin mAb (clone HPC1) from Sigma (St. Louis, MO) and
anti-VAMP Ab from Stressgen (Canada). Agarose-conjugated protein
G was from Pierce (Rockford, IL). BoNTs were kindly provided by
Drs. B.R. DasGupta and M. Goodnough (University of Wisconsin).
All other reagents were of analytical grade from Sigma.
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2.2. Peptide synthesis and puri¢cation
ESUP E (SNAP-25 [181^206]: IMEKADSNKTRIDEANQRAT-
KMLGSG) and ESUP ERDM (ESDNDTRAIKITQAGSMKRMGL-
NAKE) were synthesized by Fastmoc Fmoc chemistries in an Applied
Biosystems 431A automated solid-phase peptide synthesizer, cleaved
and puri¢ed as described [12,13].
2.3. Activation of BoNT E
The single chain BoNT E in 25 mM HEPES was converted to the
‘nicked’ di-chain form by treatment with 0.3 mg/ml trypsin XI for
30 min at 37‡C, followed by incubation with 0.5 mg/ml soybean tryp-
sin inhibitor for 15 min at room temperature. Aliquots of the nicked
toxin were frozen at 380‡C, then thawed and treated with 1 mM
dithiothreitol (DTT) immediately before use to expose the active site
of the light chain protease.
2.4. Chroma⁄n cell cultures and secretion assays
Chroma⁄n cell cultures were prepared from bovine adrenal glands
by collagenase digestion and further separated from debris and eryth-
rocytes by centrifugation on Percoll gradients as described [12,13].
Cells were maintained in monolayer cultures at a density of 625 000
cells/cm2 and were used 3^6 days after plating. All the experiments
were performed at 37‡C. Secreted [3H]noradrenaline was assayed in
digitonin-permeabilized cells as described [12,13]. The CPM released
from control cells under basal conditions was V3000, and increased
to V11 000 when stimulated with 10 WM Ca2. The total number of
counts obtained from detergent-permeabilized cells was V110 000.
Thus, the normalized basal release represents 3.5% of the total secre-
tion, and the Ca2-evoked component accounts for V10% of the
total. Statistical signi¢cance was calculated using Student’s t-test
with data from v4 independent experiments.
2.5. Immunoprecipitation of the ternary complex
SNAP-25/VAMP/syntaxin from solubilized rat brain synaptosomes
Rat brain synaptosomes were prepared from brain cortices as de-
scribed [21]. Synaptosomes (100 Wg) were solubilized in radioimmu-
noprecipitation assay bu¡er (50 mM Tris-HCl pH 7.4, 150 mM NaCl,
1% Nonidet P-40, 0.25% deoxycholate, 1 mM EGTA, 1 mM NaF,
1 mM Na3VO4, 1 mM phenylmethylsulfonyl £uoride and 5 mM
iodoacetamide), incubated with or without 100 WM ESUPs for 2 h
at 4‡C, unless otherwise indicated. Insoluble material was removed by
centrifugation at 10 000Ug for 30 min at 4‡C. Immunopuri¢cation of
the ternary complex SNAP-25/VAMP/syntaxin from the soluble ma-
terial was achieved by using an overnight incubation with anti-SNAP-
25 monoclonal antibody (1 Wg mAb/100 Wg protein). Immunocom-
plexes were captured with agarose-conjugated protein G (100 Wl,
50% slurry), and washed six times with 500 Wl of radioimmunopre-
cipitation bu¡er at 4‡C. Immunoprecipitates were dissolved with 50 Wl
of SDS-PAGE bu¡er, boiled 5 min, separated by SDS-PAGE and
analyzed by immunoblotting. Blots were probed with the anti-
SNAP-25 mAb, an anti-syntaxin mAb and an anti-VAMP Ab. Bands
were visualized using the ECL system, and quanti¢ed using the public
domain NIH Image program version 1.57 [13]. Data are given as
mean þ S.E.M., with n (number of experiments) = 3.
2.6. Inhibition of neurotransmitter release in Aplysia synapses
Experiments were performed with neuronal preparations from the
marine mollusc Aplysia californica. Intraneuronal inhibition of nerve-
evoked release of acetylcholine (ACh) was measured at identi¢ed
cholinergic synapses of Aplysia buccal ganglia [22,23]. The ganglia
were surgically removed and pinned to the Sylgard lined bottom of
an acrylic chamber, and the connective tissue capsule was excised. The
soma of identi¢ed pre- and postsynaptic cholinergic neurons were
impaled with glass microelectrodes (2^4 M6) ¢lled with 2 M potas-
sium acetate. Action potentials were evoked in presynaptic neurons by
suprathreshold depolarizing stimuli applied at 0.1 Hz. Neurotransmit-
ter release was assessed by measuring the amplitudes of inhibitory
postsynaptic currents (IPSCs) in voltage-clamped follower neurons.
Presynaptic potentials and postsynaptic currents were digitized and
stored on a personal computer using pClamp software (Axon Instru-
ments, Foster City, CA). Only responses that were not accompanied
by spontaneous activity were analyzed. The preparation was super-
fused continuously at a rate of 1 ml/min with arti¢cial sea water
containing in mM: NaCl 480; KCl 10; CaCl2 10; MgCl2 20; MgSO4
30; NaHCO3 2.5; HEPES 10, at pH 7.8, maintained at room temper-
ature. ESUP E and ESUP ERDM (5 mM) were dissolved in 600 mM
NaCl containing 1% (w/v) fast green FCF dye to aid in visualizing the
volume injected. The solution was air pressure-injected into the pre-
synaptic cell by micropipette. A maximum pressure of 60 psi was used
to introduce an adequate volume of solution into the presynaptic cell
as indicated by the appearance of intracellular dye. The volume of
solution injected was 910% of the estimated cell volume, yielding a
¢nal intracellular peptide concentration 9100 WM. BoNT E concen-
tration in the micropipette was 3.3 WM.
3. Results and discussion
3.1. A peptide mimicking the 26-aa peptide fragment released
by BoNT E cleavage of SNAP-25 blocks exocytosis
Cleavage of the C-terminus of SNAP-25 by BoNT E re-
leases a 26-mer peptide that may block neurosecretion
[12,13]. To test this hypothesis, we synthesized this 26-mer
peptide (ESUP E) and assayed the presumed inhibitory activ-
ity on Ca2-evoked catecholamine release from digitonin-per-
meabilized chroma⁄n cells. ESUP E blocked noradrenaline
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Fig. 1. ESUP E blocks Ca2-dependent catecholamine secretion
from permeabilized chroma⁄n cells. Top: Schematic representation
of SNAP-25 with the cleavage site for BoNT E. ESUP E represent
the peptide product (aa 181^206) released by BoNT E cleavage of
SNAP-25. Bottom: A: Concentration-dependent inhibition of Ca2-
evoked catecholamine release from pemeabilized chroma⁄n cells by
BoNT E, ESUP E and ESUP ERDM. Net release is given as
mean þ S.E.M. with n (number of experiments performed in tripli-
cate) = 4. Solid lines depict the best ¢t to the logistic equation:
B/Bmax = 1/(1+([blocker]/IC50)n), where B denotes the extent of
block, Bmax represents the maximal block; IC50 denotes the concen-
tration of blocker (BoNT E or ESUP E) that produces half-
maximal block, and n is the Hill coe⁄cient of the blocking activity.
For BoNT E the values were IC50 = 1.8 þ 1.3 nM, n = 0.5; and for
ESUP E, IC50 = 250 þ 75 nM, n = 0.6. B: Time course of the net
noradrenaline release (Ca2-stimulated minus basal) obtained in
presence or absence of 100 WM ESUP E or 10 nM BoNT E.
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release with an IC50=250 þ 75 nM, and a maximal inhibition
of V70% (Fig. 1A). The ESUP inhibitory activity was similar
to that elicited by BoNT E with respect to maximal inhibition
(V70%) but was V140-fold less e⁄cient (BoNT E
IC50=1.8 þ 1.3 nM). The sequence speci¢city of ESUP activity
was assessed by synthesizing a randomized version of the
peptide (ESUP ERDM), which was proven inert in blocking
catecholamine release at concentrations up to 100 WM (Fig.
1A).
To identify the step of the exocytotic cascade blocked by
ESUP E, we investigated its activity on the kinetics of the
secretory process and compared it with that produced by
BoNT E (Fig. 1B). Permeabilized cells were incubated with
ESUP E or DTT-reduced BoNT E for 5 min, and secretion
was evoked by Ca2 pulses of di¡erent duration. Incubation
of permeabilized chroma⁄n cells with 10 WM ESUP E or
10 nM BoNT E inhibited V60% of catecholamine release,
primarily by altering the slow phase of secretion (Fig. 1B),
suggesting that the vesicle pools upstream of docking and
priming steps are sensitive to the action of ESUP E and
BoNT E [24^26]. These data indicate that the 26-mer peptide
released by BoNT E cleavage of SNAP-25 is a potent and
speci¢c uncoupler of Ca2-evoked exocytosis, and suggest
that the e⁄ciency of BoNT E to disable the fusion process
may arise from the combined action of cleaving a protein
critical for the assembly of the fusion complex, and by releas-
ing a small peptide which, in turn, may interfere with the
formation of the complex.
3.2. ESUP E and BoNT E inhibit neurotransmitter release in
Aplysia cholinergic synapses in vitro
Release of ACh by the presynaptic neuron in response to
electrically evoked action potentials was assessed from the
amplitudes of the evoked IPSCs in a voltage-clamped post-
synaptic neuron. Fig. 2 shows superimposed action potentials
and IPSCs in a typical experiment. ESUP E was injected into
the presynaptic neuron at zero time (top left panel), and the
resultant decline of IPSC amplitude is shown at three succes-
sive time points. The IPSC amplitude declined to 52% of the
control value 120 min after the injection of ESUP E. The
decrease of IPSC amplitude was gradual and incomplete, typ-
ically requiring 2 h to reach a stable value of 30^70% of the
control. The time course of the e¡ect of peptides or toxin
injection on IPSC amplitude is shown in Fig. 3. BoNT E,
ESUP E or ESUP ERDM were injected at time zero. The in-
crease of IPSC amplitude immediately following the injection
of ESUP ERDM was not considered to be signi¢cant since such
increases were a frequent consequence of pressure injection of
any compound, and IPSC amplitudes typically returned to
control values within 20 min. No further reduction of re-
sponses occurred in cells injected with the random-sequence
control peptide, whereas IPSCs in cells injected with BoNT E
and active ESUP E declined to a stable level over the ensuing
120 min.
The rate and extent of IPSC inhibition caused by BoNT E
was greater than that produced by ESUP E: the amplitude
was attenuated by 50% in 28 min and by 90% in 120 min by
BoNT E, whereas inhibition by ESUP E was only 50% at 120
min. The more rapid and nearly complete IPSC decrement
caused by BoNT E supports the concept that the inhibition
caused by the toxin protease is a consequence of both a de-
crease in available SNAP-25 and an accumulation of cleavage
products.
3.3. ESUP E inhibits vesicle docking by interfering with the
formation of the ternary complex comprising SNAP-25,
VAMP, and syntaxin
Since the C-terminal domain of SNAP-25 binds tightly to
VAMP and syntaxin during vesicle docking, forming a highly
stable ternary complex, it is conceivable that ESUP E blocks
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Fig. 3. ESUP E and BoNT E inhibit IPSC amplitude in Aplysia
buccal ganglion synapses. Active ESUP E (n = 10), the inactive ran-
dom sequence ESUP ERDM analog (n = 8), or BoNT E (n = 7) were
injected into the presynaptic neuron at zero time. IPSC amplitude
was inhibited after injection of active ESUP E and BoNT E but not
by injection of the inactive analog. Mean þ S.E.M.
Fig. 2. ESUP E blocks ACh release by the presynaptic neuron in a
cholinergic synapse in Aplysia buccal ganglia. ACh release was
monitored as the amplitude of the IPSC (lower trace) elicited by an
evoked action potential (upper trace) in the presynaptic neuron. Re-
cordings show the decrement of the IPSC amplitude after injection
of ESUP E into the presynaptic neuron at zero time.
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the docking process by competition with SNAP-25 for binding
to the ternary complex. To examine this question, we studied
the e¡ect of ESUP E on the interaction of SNARE proteins in
digitonin-permeabilized chroma⁄n cells. We did not observe
coimmunoprecipitation of all the SNARE proteins with the
anti-SNAP-25 mAb (data not shown), as reported by others
[27]. We therefore turned to rat brain synaptosomes as an
alternative preparation [3,20,28]. Since the SNARE complex
forms spontaneously during synaptosome preparation and
solubilization, we evaluated if ESUP E could displace
SNAP-25 from the ternary complex and, therefore, dissociate
the preformed aggregate or interfere with its assembly. The
experimental protocol involved detergent solubilization of
synaptosomes, incubation with ESUP E or ESUP ERDM, im-
munopuri¢cation of the ternary complex using an anti-SNAP-
25 mAb followed by separation of the components using
SDS-PAGE. Immunoblots probed with speci¢c antibodies
raised against syntaxin, SNAP-25 and VAMP revealed the
presence of the three proteins in the immunoprecipitate (Fig.
4A). Incubation with 100 WM ESUP E inhibited the coimmu-
precipitation of VAMP and syntaxin without a¡ecting the
immunopuri¢cation of SNAP-25.
A quantitative analysis of the immunoblots is shown in Fig.
4B. An excess of ESUP E inhibited the coimmunoprecipita-
tion of VAMP by V30% and of syntaxin by V40%, whereas
no e¡ect was detected with ESUP ERDM, in accord with
expectations. The partial inhibition produced by ESUP E
(100 WM) may be accounted for by its relatively low a⁄nity
(Fig. 1A). Nonetheless, the fact that a short peptide may
interfere with the assembly or stability of an SDS-resistant
complex is highly signi¢cant, and provides experimental sup-
port for the notion that ESUP E inhibits vesicle docking by
preventing the formation of the essential ternary complex.
These ¢ndings suggest that ESUP E may compete with
SNAP-25 for binding to VAMP and interrupt the ensuing
chain of protein-protein interactions that lead to vesicle fu-
sion.
3.4. Molecular mechanism of ESUPs biological activity
The ¢nding that the 26-mer peptide released from SNAP-25
cleavage by BoNT E mimics the inhibitory action of this
neurotoxin on neurosecretion (Fig. 1), and on synaptic trans-
mission (Figs. 2 and 3), provides support to the tenet that
BoNTs abrogate vesicle fusion by the combined action of
cleaving the substrate and releasing peptide products which
block the docking or/and priming steps of the exocytotic cas-
cade. The result that the ternary complex is speci¢cally dis-
rupted by an excess of ESUP E (Fig. 4) supports this view.
The fact that the 20-mer ESUP A (SNAP-25 [187^206]:
SNKTRIDEANQRATKMLGSG), corresponding to the C-
terminal sequence of SNAP-25, arrests the ATP-dependent
maturation of the secretory granules and promotes the accu-
mulation of secretory vesicles near the plasma membrane is in
accord with this notion [13]. Recent studies implicate the C-
terminal segment of SNAP-25 encompassing residues 180^196
in vesicle docking and in a late post-docking step [29,30]. Our
¢nding that ESUP E is a more e⁄cient inhibitor of neuro-
secretion than ESUP A supports this conclusion. Thus,
ESUPs mimicking speci¢c protein domains provide novel
tools to dissect their contribution to di¡erent steps of neuro-
secretion.
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